Millennium Management
QNCX icon

Millennium Management’s Quince Therapeutics QNCX Stock Holding History

Millennium Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-500
Closed -$1.26M – 7378
2021
Q4 		$1.26M Buy
500
+375
+300% +$2.29M ﹤0.01% 4188
2021
Q3 		$2.29M Buy
+125
New +$1.99M ﹤0.01% 3750

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Millennium Management's QNCX Position: Q1 2026 in Review

Millennium Management increased its Quince Therapeutics (QNCX) stake by 110% in Q1 2026, buying an estimated $1.32M and bringing the position to 12,519 shares worth $254K. The position accounts for ﹤0.01% of the portfolio, ranked #5074.

Millennium Management first reported a position in QNCX in Q2 2019 and has held it in 22 quarters since. The position peaked at $7.15M in Q4 2021. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Millennium Management held 12,519 shares of Quince Therapeutics worth $254K as of Q1 2026.
  • Millennium Management bought 6,567 Quince Therapeutics shares in Q1 2026, an estimated $1.32M.
  • Quince Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #5074 holding.
  • Millennium Management first reported a position in Quince Therapeutics in Q2 2019 and has held it in 22 quarters since.
  • Millennium Management's Quince Therapeutics position peaked at $7.15M in Q4 2021.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.